Specialty pharmacy can benefit from having definitive a center of excellence model that caters to respective therapies and disease states.
An implantable form of naltrexone was more effective in improving HIV outcomes in patients compared with oral naltrexone.
Top news of the day from across the health care landscape.
Rizaport is an oral film formulation of rizatriptan benzoate, the active drug in Maxalt, for patients with migraine who experience dysphagia or migraine-related nausea.
The daratumumab (Darzalex) combination therapy would be the first for use in the frontline setting for transplant-eligible patients with multiple myeloma.
Top news of the day from across the health care landscape.
HIV infection is associated with higher rates of hepatitis C replication.

Most Popular

Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.